贝伐珠单抗联合新辅助治疗后继以间歇性减瘤术治疗晚期卵巢癌的疗效与安全性:ANTHALYA 试验结果
ANTHALYA 是一项多中心、开放标签、非对照 II 期研究,95 例初治不可切除的 FIGO IIIC/IV 期卵巢、输卵管或腹膜腺癌患者按 2:1 随机接受 4 周期新辅助卡铂-紫杉醇(CP)联合或不联合 3 周期贝伐珠单抗 15 mg/kg,随后行间歇性减瘤术。贝伐珠单抗联合 CP 组(BCP 组)完全切除率为 58.6%,高于预设参考值 45%,达到主要目标;两组总体毒性未见 BCP 组增多,预设安全性停止规则未触发。
要点
- BCP 组间歇性减瘤术完全切除率 58.6%,高于预设参考值 45%。
- BCP 组与 CP 组 3 级及以上不良事件发生率分别为 62% 和 63%。
- 预设的贝伐珠单抗相关安全性停止规则未被触发。
核心结论
- 主要目标已达到,BCP 组完全切除率显著高于参考值。
- 作者认为,对于评估为不能理想切除的患者,无论最终手术决定如何,均可将贝伐珠单抗安全地加入术前方案;贝伐珠单抗在该场景中的作用应进一步研究。
研究设计与样本
- 多中心、开放标签、非对照 II 期研究。
- 95 例初治不可切除的 FIGO IIIC/IV 期卵巢、输卵管或腹膜腺癌患者,按 2:1 随机分组。
- 接受 4 周期新辅助 CP 联合或不联合 3 周期贝伐珠单抗 15 mg/kg,随后行间歇性减瘤术。
主要发现
- BCP 组(N=58)中 40 例(69%)接受间歇性减瘤术,其中 85% 达到完全切除,该组完全切除率为 58.6%(34 例)。
- CP 组完全切除率为 51.4%:22 例(60%)接受间歇性减瘤术,其中 85% 达到完全切除。
- 3 级及以上不良事件发生率 BCP 组 62% vs CP 组 63%,主要为血液及淋巴系统、胃肠道和血管疾病,BCP 组毒性未增多。
- 术后并发症(主要为伤口、感染和胃肠道并发症)发生率 BCP 组 28% vs CP 组 36%。
- 预设安全性停止规则未达到。
关键数值与推荐
- 主要目标为评估 BCP 组间歇性减瘤术时的完全切除率,参考完全切除率定义为 45%。
- BCP 组完全切除率 58.6%(34 例),经统计学检验高于预设的 45%。
- 贝伐珠单抗剂量为 15 mg/kg,与新辅助 CP 同步使用 3 周期。
临床怎么用
- 作者认为,对于评估为不能理想切除的患者,无论最终手术决定如何,均可将贝伐珠单抗安全地加入术前方案;贝伐珠单抗在该场景中的作用应进一步研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To investigate whether adding bevacizumab to neoadjuvant carboplatin-paclitaxel (CP) helps achieve optimal debulking, measured by complete resection rate (CRR) at interval debulking surgery (IDS), in patients with initially unresectable International Federation of Gynecology and Obstetrics stage IIIC/IV ovarian, tubal or peritoneal adenocarcinoma. METHODS: Multicentre, open-label, non-comparative phase II study. Ninety-five patients randomised (2:1) to receive four cycles of neoadjuvant CP ±3 concomitant cycles of bevacizumab 15 mg/kg (BCP) followed by IDS. Primary objective is to evaluate the CRR at IDS in the BCP group (reference CRR rate defined as 45% CRR). A stopping rule based on bevacizumab-related adverse events (AEs) of special interest was implemented. RESULTS: In the BCP group (N = 58), IDS was performed in 40 (69%) patients, of whom 85% had a complete resection. The CRR of this group was therefore 58.6% (34 patients), statistically over pre-defined 45%. The CRR in the CP group was 51.4%: 22 (60%) patients underwent IDS (85% had a complete resection). Grade ≥3 adverse events occurred in 62% of the BCP-treated patients and 63% of the CP-treated patients: mainly blood and lymphatic, gastrointestinal and vascular disorders, without more toxicity with BCP. Postoperative complications (mainly wound, infectious and gastrointestinal complications) occurred in 28% and 36% of the patients, respectively. The pre-specified safety stopping rule was not reached. CONCLUSION: The primary objective was met as the CRR with BCP was significantly higher than the reference rate. Bevacizumab may be safely added to a preoperative program in patients deemed non-optimally resectable, whatever the final surgical decision. Bevacizumab's role in this setting should be further investigated.
引用
- Rouzier R, Gouy S, Selle F, et al. Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial. Eur J Cancer. 2016. PMID: 27914243. doi:10.1016/j.ejca.2016.09.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。